Literature DB >> 1708947

Lineage-restricted clonality in biphasic solid tumors.

J A Fletcher1, G S Pinkus, N Weidner, C C Morton.   

Abstract

Cytogenetic analysis of two pulmonary chondroid hamartomas and nine breast adenofibromas revealed clonal chromosome aberrations in both hamartomas and in four breast tumors. To determine lineage of the cells with chromosome aberrations, a combined immunohistochemical/cytogenetic approach was developed that enabled simultaneous ascertainment of cytogenetic aberrations and immunohistochemical features in individual cells. Immunohistochemical/cytogenetic evaluation of one hamartoma and two adenofibromas demonstrated that neoplastic proliferation, in each case, was confined to the mesenchymal (stromal) component, whereas epithelial cells appeared to be reactive. Cytogenetically abnormal short-term cultures of the remaining hamartoma and another of the breast adenofibromas were composed entirely of mesenchymal elements, indicating mesenchymal clonality in those tumors as well. Our findings support redesignation of pulmonary chondroid hamartomas as 'pulmonary chondromas' and suggest that carcinomas developing within fibroadenomas arise from reactive epithelial proliferation. Combined immunohistochemical/cytogenetic analysis might be useful in the development of novel therapeutic approaches that selectively target neoplastic populations within solid tumors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1708947      PMCID: PMC1886025     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

1.  The problem of carcinoma developing in a fibroadenoma: recent experience at Memorial Hospital.

Authors:  E Y Fondo; P P Rosen; A A Fracchia; J A Urban
Journal:  Cancer       Date:  1979-02       Impact factor: 6.860

2.  Histologic and cytogenetic observations on a case of giant fibroadenoma.

Authors:  C D Olinici; G Simu
Journal:  Neoplasma       Date:  1970       Impact factor: 2.575

3.  So-called hamartoma of the lung--a true neoplasm of fibrous connective tissue of the bronchi.

Authors:  E M Bateson
Journal:  Cancer       Date:  1973-06       Impact factor: 6.860

4.  Pulmonary hamartoma.

Authors:  C Butler; J Kleinerman
Journal:  Arch Pathol       Date:  1969-12

5.  The ultrastructure of pulmonary hamartoma.

Authors:  F J Stone; A M Churg
Journal:  Cancer       Date:  1977-03       Impact factor: 6.860

6.  The management of patients with carcinomas in fibroadenomatous tumors of the breast.

Authors:  L Ozzello; F E Gump
Journal:  Surg Gynecol Obstet       Date:  1985-02

7.  Lobular carcinoma arising in fibroadenoma of the breast.

Authors:  K Buzanowski-Konakry; E G Harrison; W S Payne
Journal:  Cancer       Date:  1975-02       Impact factor: 6.860

8.  Fibroblast-mediated acceleration of human epithelial tumor growth in vivo.

Authors:  J L Camps; S M Chang; T C Hsu; M R Freeman; S J Hong; H E Zhau; A C von Eschenbach; L W Chung
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

9.  Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia.

Authors:  M Keinänen; J D Griffin; C D Bloomfield; J Machnicki; A de la Chapelle
Journal:  N Engl J Med       Date:  1988-05-05       Impact factor: 91.245

10.  Most cystosarcoma phyllodes and fibroadenomas have progesterone receptor but lack estrogen receptor: stromal localization of progesterone receptor.

Authors:  B R Rao; J S Meyer; C G Fry
Journal:  Cancer       Date:  1981-04-15       Impact factor: 6.860

View more
  12 in total

Review 1.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  Mammary epithelial hyperplasias: alterations related solely to proliferation?

Authors:  R R Burbano; J B Neto; P M Philbert; C Casartelli
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  Simultaneous interphase cytogenetic analysis and fluorescence immunophenotyping of dedifferentiated chondrosarcoma. Implications for histopathogenesis.

Authors:  J A Bridge; J DeBoer; J Travis; S L Johansson; G Elmberger; S M Noel; J R Neff
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

4.  HMGI(Y) activation by chromosome 6p21 rearrangements in multilineage mesenchymal cells from pulmonary hamartoma.

Authors:  S Xiao; M L Lux; R Reeves; T J Hudson; J A Fletcher
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

Review 5.  Significance of rat mammary tumors for human risk assessment.

Authors:  Jose Russo
Journal:  Toxicol Pathol       Date:  2014-05-28       Impact factor: 1.902

6.  Chromosomal Translocation t(5;12)(p13;q14) Leading to Fusion of High-mobility Group AT-hook 2 Gene With Intergenic Sequences From Chromosome Sub-Band 5p13.2 in Benign Myoid Neoplasms of the Breast: A Second Case.

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Kristin Andersen; Marius Lund-Iversen; Hanne Regine Hognestad; Ingvild Lobmaier; Francesca Micci; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2022 Jul-Aug       Impact factor: 3.395

7.  Chromosome aberrations in mesoblastic nephroma.

Authors:  D E Schofield; E J Yunis; J A Fletcher
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

Review 8.  Histogenetic concepts, terminology and categorization of biphasic tumours of the oral and maxillofacial region.

Authors:  Arvind Babu R S; Ramana Reddy B V; Anuradha C H
Journal:  J Clin Diagn Res       Date:  2014-02-03

9.  Demonstration of polyclonal origin of giant fibroadenoma of the breast.

Authors:  S Noguchi; T Aihara; K Motomura; H Inaji; S Imaoka; H Koyama; H Tanaka
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  Recombinations of chromosomal bands 6p21 and 14q24 characterise pulmonary hamartomas.

Authors:  M Johansson; C Dietrich; N Mandahl; G Hambraeus; L Johansson; P P Clausen; F Mitelman; S Heim
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.